Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Börse Stuttgart			5-day change	1st Jan Change
- ^EUR	-.--%		+2,227.27%	+1,349.60%

25/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI
25/09	SRX Global Makes Investment in Onconetix	MT

Market Cap	2.9M 2.57M 2.4M 2.19M 4.13M 279M 4.17M 29.08M 11.27M 142M 10.88M 10.64M 457M	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-2.27M -2.02M -1.89M -1.72M -3.24M -219M -3.27M -22.83M -8.84M -112M -8.54M -8.35M -359M	EV / Sales 2024	5,556,319x	EV / Sales 2025	-3,367,890x
Free-Float	99.85%	Yield 2024 *	-	Yield 2025	-

25/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI
25/09	SRX Global Makes Investment in Onconetix	MT
01/09	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
14/08	Onconetix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Onconetix, Inc. announced that it expects to receive $780.2496 million in funding	CI
19/05	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
19/05	Realbotix provides update on Nasdaq listing	RE
13/05	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
25/04	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
25/04	Onconetix, Inc. Announces Board and Committee Changes	CI
01/04	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
25/03	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE
25/03	Onconetix, Inc. Announces Chief Executive Officer Changes, Effective March 18, 2026	CI

14/09/23	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
27/04/23	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
09/12/22	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

Onconetix, Inc. Stock Börse Stuttgart

Stocks

J4T0

US68237Q1040

Pharmaceuticals

Valuation: Onconetix, Inc.

Latest news: Onconetix, Inc.

Last Transcript: Onconetix, Inc.

Analysts' recommendations: Onconetix, Inc.

Press Releases: Onconetix, Inc.

News in other languages: Onconetix, Inc.

Managers and Directors: Onconetix, Inc.

Biopharmaceuticals

Financials

Company Profile

25/09	SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)	AQ
14/09	Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition	AQ
03/09	Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events	AQ
06/08	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series	AQ
05/08	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG	AQ

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	18/03/2026
Karina Fedasz CEO	Chief Executive Officer	53	02/04/2025

Director	Title	Age	Since
Sarah Romano BRD	Director/Board Member	46	05/12/2025
Sammy Dorf CHM	Chairman	41	23/04/2026
Joshua Epstein BRD	Director/Board Member	-	23/04/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	-.--%	+2,227.27%	-	-	2.9M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+39.40%	+112.31%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+37.67%	+65.02%	617B
ABBVIE INC.	+1.11%	-0.58%	+11.10%	+77.28%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.21%	+40.71%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+21.60%	+39.37%	333B
NOVARTIS AG	-1.46%	-2.89%	+11.84%	+24.60%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-4.69%	+8.40%	244B
AMGEN INC.	-1.04%	-2.79%	+35.52%	+51.34%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+30.92%	+95.33%	179B
Average	-0.21%	-3.39%	+27.17%	+57.15%	410.8B
Weighted average by Cap.	+0.42%	-3.33%	+30.52%	+68.96%

	2024	2025
Net sales	2.52 2.24 2.09 1.91 3.6 242.65 3.63 25.33 9.82 124.05 9.48 9.27 398.11	0.82 0.72 0.68 0.62 1.16 78.38 1.17 8.18 3.17 40.07 3.06 2.99 128.6
Net income	-58.69M -52.15M -48.67M -44.36M -83.67M -5.64B -84.44M -589M -228M -2.88B -220M -216M -9.26B	-14.03M -12.47M -11.64M -10.61M -20M -1.35B -20.19M -141M -54.57M -690M -52.68M -51.54M -2.21B
Net Debt	8.8M 7.82M 7.3M 6.65M 12.55M 846M 12.66M 88.32M 34.23M 433M 33.04M 32.33M 1.39B	-5.17M -4.6M -4.29M -3.91M -7.37M -497M -7.44M -51.9M -20.11M -254M -19.42M -19M -816M